The cyclin-dependent kinase inhibitor p57(Kip2) is epigenetically regulated in carboplatin resistance and results in collateral sensitivity to the CDK inhibitor seliciclib in ovarian cancer

BACKGROUND: Carboplatin remains a first-line agent in the management of epithelial ovarian cancer (EOC). Unfortunately, platinum-resistant disease ultimately occurs in most patients. Using a novel EOC cell line with acquired resistance to carboplatin: PEO1CarbR, genome-wide micro-array profiling ide...

Descripción completa

Detalles Bibliográficos
Autores principales: Coley, H M, Safuwan, N A M, Chivers, P, Papacharalbous, E, Giannopoulos, T, Butler-Manuel, S, Madhuri, K, Lovell, D P, Crook, T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3273354/
https://www.ncbi.nlm.nih.gov/pubmed/22233925
http://dx.doi.org/10.1038/bjc.2011.566

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3273354/
https://www.ncbi.nlm.nih.gov/pubmed/22233925
http://dx.doi.org/10.1038/bjc.2011.566

Ejemplares similares